Brief: Dermata Therapeutics Inc - Positive Results From DMT410 Phase 1B Proof Of Concept Study For Aesthetic Skin Conditions

Dermata Therapeutics

19/11/2021 14:14

Nov 19 (Reuters) - Dermata Therapeutics Inc  DRMA.O :
    * DERMATA THERAPEUTICS INC - POSITIVE RESULTS FROM DMT410
PHASE 1B
PROOF OF CONCEPT STUDY FOR AESTHETIC SKIN CONDITIONS
    * DERMATA THERAPEUTICS INC - OBSERVED IMPROVEMENTS IN PORE
SIZE,
LUMINOSITY, BRIGHTNESS, AND OVERALL AESTHETIC APPEARANCE
    * DERMATA THERAPEUTICS INC - DURATION OF EFFECT LASTED
APPROXIMATELY 3 MONTHS
    * DERMATA THERAPEUTICS INC - NO POTENTIAL DISTANT SPREAD OF
TOXIN
OBSERVED
    * DERMATA THERAPEUTICS - DMT410 GENERALLY SAFE, WELL
TOLERATED
WITH NO ADVERSE EVENTS REPORTED, NO WITHDRAWALS DUE TO
TREATMENT-RELATED ADVERSE EVENTS

Source text for Eikon:  ID: 
Further company coverage:  DRMA.O 

 ((Reuters.Briefs@thomsonreuters.com;))